Case Report: Tocilizumab for the Treatment of SARS-CoV-2 Infection in a Patient With Aplastic Anemia

Frontiers in Oncology

卷:10

Zachary French¹  Joanne Filicko-O'Hara²  Usama Gergis²  Lindsay Wilde²  Gina Keiffer²  Adam F. Binder² 

[1] Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, United States;

[2] Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States;

关键词: COVID-19;    SARS-CoV-2;    tocilizumab;    cytokine storm;    aplastic anemia;   

DOI  :  10.3389/fonc.2020.562625

来源: DOAJ

【 摘 要 】

While cytokine storm develops in a minority of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, novel treatment approaches are desperately needed for those in whom it does. Tocilizumab, an interleukin-6 receptor antibody, has been utilized for the treatment of cytokine storm in a number of severe inflammatory conditions, including in patients with severe coronavirus disease 2019 (COVID-19). Here, we present the first published case utilizing this therapy in a patient with underlying immunodeficiency. Our patient with aplastic anemia developed cytokine storm due to COVID-19 manifested by fever, severe hypoxia, pulmonary infiltrates, and elevated inflammatory markers. Following treatment with tocilizumab, cytokine storm resolved, and the patient was ultimately safely discharged from the hospital.

【 授权许可】

Unknown